Carbamazepine

The Treatment of Epilepsy: Third Edition

Volumn , Issue , 2009, Pages 459-474

  Sillanpää, Matti ^a   Haataja, Leena ^a   Tomson, Torbjörn ^b   Johannessen, Svein I ^c  

^a UNIVERSITY OF TURKU   (Finland)

^b Karonlinska University Hospital   (Sweden)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Benign epilepsy with centrotemporal spikes; Carbamazepine; Cutaneous hypersensitivity reactions; Interactions between carbamazepine and AEDs; Pharmacodynamic interactions carbamazepine and drugs; Serum concentration and dosage; Serum level monitoring

Indexed keywords

EID: 84872089826     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444316667.ch36     Document Type: Chapter

References (88)

1. Thiele J, Holzinger O. Ueber o-Diamidodibenzyl. Justus Liebig's Annalen des Chemie 1899; 305: 96-102.
2. Faigle JW, Feldman KF. Carbamazepine, chemistry and biotransformation. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic Drugs, 4th edn. New York: Raven Press, 1995; 499-513.
3. Theobald W, Kunz HA. Pharmacology of the antiepileptic drug 5-carbamyl-5H-dibenzo [b,f]azepine. Arzneimittelforschung 1963; 13: 122-125.
4. McLean MJ, MacDonald RL. Carbamazepine and carbamazepine 10,11-epoxide produce use and voltage-dependent limitation of rapid firing action potentials of mouse central neurons in cell. J Pharmacol Exp Ther 1986; 238: 727-738.
5. Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs. Nature Rev Neurosci 2004; 5: 553-564.
6. Liu L, Zheng T, Morris MJ, et al. The mechanism of carbamazepine aggravation of absence seizures. J Pharmacol Exp Ther 2006; 319: 790-798.
7. Kuo CC. A common anticonvulsant binding site for phenytoin, carbamazepine, and lamotrigine in neuronal Na+ channels. Mol Pharmacol 1998; 54: 712-721.
8. Johannessen Landmark C. Relations between mechanisms of action and clinical efficacy of antiepileptic drugs in non-epilepsy conditions. CNS Drugs 2008; 22: 27-47.
9. Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nature Med 2004; 10: 685-692.
10. Anmann B, Grünze H, Vieta E, et al. Antiepileptic drugs and mood stability. Clin EEG Neurosci 2007; 38: 116-123.
11. Chetcuti A, Adams LJ, Mitchell PB, Schofield PR. Altered gene expression in mice treated with the mood stabilizer sodium valproate. Int J Neuropsychopharmacol 2005; 28: 1-10.
12. Morselli PL. Carbamazepine: absorption, distribution and excretion. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic Drugs, 4th edn. New York: Raven Press, 1995; 515-528.
13. Bialer M. Pharmacokinetic evaluation of sustained release formulations of antiepileptic drugs. Clin Pharmacokinet 1992; 22: 11-21.
14. Bialer M. Generic products of antiepileptic drugs (AEDs): is it an issue? Epilepsia 2007; 48: 1825-1832.
15. Johannessen SI, Henriksen O, Munthe-Kaas AW, Salvesen B. Serum concentration profile studies of tablets and suppositories of valproate and carbamazepine in healthy subjects and patients with epilepsy. In: Levy RH, Pitlick WH, Eichelbaum M, Meijer J, eds. Metabolism of Antiepileptic Drugs. New York: Raven Press, 1984; 61-71.
16. Morselli PL, Baruzzi A, Gerna M, et al. Carbamazepine and carbamazepine-10,11-epoxide concentration in human brain. Br J Clin Pharmacol 1977; 4: 535-540.
17. Kudriakova TB, Sirota LA, Rozova GI, Gorkov VA. Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites. Br J Clin Pharmacol 1992; 33: 611-615.
18. Battino D, Croci D, Rossini A, Messina S, Mamoli D, Perucca E. Serum carbamazepine concentrations in elderly patients: a case-matched pharmacokinetic evaluation based on therapeutic drug monitoring data. Epilepsia 2003; 44: 923-929.
19. Brodtkorb E, Reimers A. Seizure control and pharmacokinetics of antiepileptic drugs in pregnant women with epilepsy. Seizure 2008; 17: 160-165.
20. Tomson T, Lindbom U, Ekqvist B, Sundqvist A. Epilepsy and pregnancy: a prospective study of seizure control in relation to free and total plasma concentrations of carbamazepine and phenytoin. Epilepsia 1994; 35: 122-130.
21. Tomson T, Lindbom U, Ekqvist B, Sundqvist A. Disposition of carbamazepine and phenytoin in pregnancy. Epilepsia 1994; 35: 131-135.
22. Hägg S, Spigset O. Anticonvulsant use during lactation. Drug Saf 2000; 22: 425-440.
23. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurology 2003; 2: 347-356.
24. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurology 2003; 2: 473-481.
25. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006; 61: 246-255.
26. Perucca E, Cloyd J, Critchley D, Fuseau E. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia 2008; 49: 1123-1141.
27. Kim K, Oh S, Park P, Park J. Effect of probenecid on the pharmacokinetics of carbamazepine in healthy subjects. Eur J Clin Pharmacol 2005; 61: 275-280.
28. Tomson T, Dahl M, Kimland E. Therapeutic monitoring of antiepileptic drugs for epilepsy. Cochrane Database Syst Rev 2007; 1: CD002216.
29. Patsalos P, Berry D, Bourgeois B, et al. Antiepileptic Drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on therapeutic strategies. Epilepsia 2008; 49: 1239-1276.
30. Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006; 47: 1094-1120.
31. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondary generalized tonic-clonic seizures. N Engl J Med 1985; 313: 145-151.
32. Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med 1992; 327: 765-771.
33. Chadwick D, for the Vigabatrin European Monotherapy Study Group. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Lancet 1999; 354: 13-19.
34. Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ, for the Levetiracetam Monotherapy Study Group. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007; 68: 402-408.
35. Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet 1995; 345: 476-479.
36. Privitera MD, Brodie MJ, Mattson RH, Chadwick DW, Neto W, Wang S; EPMN 105 Study Group. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003; 107: 165-175.
37. Dam M, Ekberg R, Løyning Y, Waltimo O, Jakobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989; 3: 70-76.
38. Marson AG, Al-Kharusi AM, Alwaidh M, et al, on behalf of the SANAD Study Group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomized comparison. Lancet 2007; 369: 1000-1015.
39. Richens A, Davidson DL, Cartlidge NE, Easter DJ. A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy. Adult EPITEG Collaborative Group. J Neurol Neurosurg Psychiatry 1994; 57: 682-687.
40. Heller AJ, Chesterman P, Elwes RD, Crawford P, et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. J Neurol Neurosurg Psychiatry 1995; 58: 44-50.
41. Brodie MJ, Overstall PW, Giorgi L. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res 1999; 37: 81-87.
42. Rowan AJ, Ramsay RE, Collins JF, et al. VA Cooperative Study 428 Group. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 2005; 64: 1868-1873.
43. Saetre E, Perucca E, Isojärvi J, et al. On behalf of the LAM 40089 Study Group. An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia 2007; 48: 1292-1302.
44. Verity CM, Hosking G, Easter DJ. A multicentre comparative trial of sodium valproate and carbamazepine in paediatric epilepsy. The Paediatric EPITEG Collaborative Group. Dev Med Child Neurol 1995; 37: 97-108.
45. de Silva M, MacArdle B, McGowan M, et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet 1996; 347: 709-713.
46. Callaghan N, Kenny RA, O'Neill B, Crowley M, Goggin T. A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. J Neurol Neurosurg Psychiatry 1985; 48: 639-644.
47. Marson AG, Williamson PR, Clough H, et al. Carbamazepine versus valproate monotherapy for epilepsy: a meta-analysis. Epilepsia 2002; 43: 505-513.
48. Tudur Smith C, Marson AG, Clough HE, Williamson PR. Carbamazepine versus phenytoin monotherapy for epilepsy. Cochrane Database Syst Rev 2002: CD001911.
49. Perucca E, Gram L, Avanzini G, Dulac O. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998; 39: 5-17.
50. Genton P. When antiepileptic drugs aggravate epilepsy. Brain Dev 2000; 2: 75-78.
51. Barcs G, Walker EB, Elger CE, et al. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia 2000; 41: 1597-1607.
52. Besag FM, Berry DJ, Pool F, Newbery JE, Subel B. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? Epilepsia 1998; 39: 183-187.
53. Blom S. Trigeminal neuralgia: its treatment with a new anticonvulsant drug (G-32883). Lancet 1962; 1(7234): 839-840.
54. Spina E, Perugi G. Antiepileptic drugs: indications other than epilepsy. Epileptic Disord 2004; 6: 57-75.
55. Chadwick DW, Anhut H, Greiner MJ, et al. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945-77. Neurology 1998; 51: 1282-1288.
56. Arroyo S, Sander JW. Carbamazepine in comparative trials: pharmacokinetic characteristics too often forgotten. Neurology 1999; 53: 1170-1174.
57. Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia 2007; 48: 1223-1244.
58. Kälviäinen R, Äikiä M, Saukkonen AM, Mervaala E, Riekkinen PJ Sr. Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy. A randomized, controlled study. Arch Neurol 1995; 52: 989-996.
59. Smith D, Mattson R, Cramer J, et al. Results of a nationwide Veterans Administration Cooperative Study comparing the efficacy and toxicity of carbamazepine, phenobarbital, phenytoin, and primidone. Epilepsia 1987; 28(Suppl. 3): 50-58.
60. Prevey ML, Delaney RC, Cramer JA, Cattanach L, Collins JF, Mattson RH. Effect of valproate on cognitive functioning. Comparison with carbamazepine. The Department of Veterans Affairs Epilepsy Cooperative Study 264 Group. Arch Neurol 1996; 53: 1008-1016.
61. Aldenkamp AP, Alpherts WC, Blennow G, et al. Withdrawal of antiepileptic medication in children-effects on cognitive function: the Multicenter Holmfrid Study. Neurology 1993; 43: 41-50.
62. Meador KJ, Gevins A, Loring DW, et al. Neuropsychological and neurophysiologic effects of carbamazepine and levetiracetam. Neurology 2007; 69: 2076-2084.
63. Perry S, Holt P, Benatar M. Levetiracetam versus carbamazepine monotherapy for partial epilepsy in children less than 16 years of age. J Child Neurol 2008; 23: 515-519.
64. Âikiä M, Jutila L, Salmenperä T, Mervaala E, Kälviäinen R. Comparison of the cognitive effects of tiagabine and carbamazepine as monotherapy in newly diagnosed adult patients with partial epilepsy: pooled analysis of two long-term, randomized, follow-up studies. Epilepsia 2006; 47: 1121-1127.
65. Alvestad S, Lydersen S, Brodtkorb E. Cross-reactivity pattern of rash from current aromatic antiepileptic drugs. Epilepsy Res 2008; 80: 194-200.
66. Tennis P, Stern RS. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology 1997; 49: 542-546.
67. Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005; 64: 1134-1138.
68. Hung SI, Chung WH, Jee SH, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006; 16: 297-306.
69. Lonjou C, Thomas L, Borot N, et al. The RegiSCAR Group. A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J 2006; 6: 265-268.
70. Ibanez L, Vidal X, Ballarin E, Laporte JR. Population-based drug-induced agranulocytosis. Arch Internal Med 2005; 165: 869-874.
71. Askmark H, Wiholm B. Epidemiology of adverse drug reactions to carbamazepine as seen in a spontaneous reporting system. Acta Neurol Scand 1990; 81: 131-140.
72. Van Amelsvoort T, Bakshi R, Devaux CB, Schwabe S. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review. Epilepsia 1994; 35: 181-188.
73. Simko J, Horacek J. Carbamazepine and risk of hypothyroidism: a prospective study. Acta Neurol Scand 2007; 116: 317-321.
74. Vainionpää LK, Mikkonen K, Rättyä, et al. Thyroid function in girls with epilepsy with carbamazepine, oxcarbazepine, or valproate monotherapy and after withdrawal of medication. Epilepsia 2004; 45: 197-203.
75. Isojärvi J. Disorders of reproduction in patients with epilepsy: antiepileptic drug related mechanisms. Seizure 2008; 17: 111-119.
76. Lossius MI, Tauboll E, Mowinckel P, Morkrid L, Gjerstad L. Reversible effects of antiepileptic drugs on reproductive endocrine function in men and women with epilepsy-a prospective randomized double-blind withdrawal study. Epilepsia 2007; 48: 1875-1882.
77. Pack AM, Morrell MJ, Marcus R, et al. Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. Ann Neurol 2005; 57: 252-257.
78. Pack AM, Morrell MJ, Randall A, McMahon DJ, Shane E. Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy. Neurology 2008; 70: 1586-1593.
79. Kasarskis EJ, Kuo CS, Berger R, Nelson KR. Carbamazepine-induced cardiac dysfunction. Characterization of two distinct clinical syndromes. Arch Intern Med 1992; 152: 186-191.
80. Kennebäck G, Bergfeldt L, Tomson T, Spina E, Edhag O. Carbamazepine induced bradycardia-a problem in general or only in susceptible patients? A 24-h long-term electrocardiogram study. Epilepsy Res 1992; 13: 141-145.
81. Tomson T, Battino D, French J, et al. Antiepileptic drug exposure and major congenital malformations: the role of pregnancy registries. Epilepsy Behav 2007; 11: 277-282.
82. Arpino C, Brescianini S, Robert E, et al. Teratogenic effects of antiepileptic drugs: use of an International Database on Malformations and Drug Exposure (MADRE). Epilepsia 2000; 41: 1436-1443.
83. Rosa FW. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med 1991; 324: 674-677.
84. Gaily E, Kantola-Sorsa E, Hiilesmaa V, et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology 2004; 62: 28-32.
85. Wide K, Winbladh B, Tomson T, Kallen B. Body dimensions of infants exposed to antiepileptic drugs in utero: observations spanning 25 years. Epilepsia 2000; 41: 854-861.
86. Gillham R, Kane K, Bryant-Comstock L, Brodie MJ. A double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health-related quality of life as an outcome measure. Seizure 2000; 9: 375-379.
87. Weaver DF, Camfield P, Fraser A. Massive carbamazepine overdose: clinical and pharmacologic observations in five episodes. Neurology 1988; 38: 755-759.
88. Perucca E, Dulac O, Shorvon S, Tomson T. Harnessing the clinical potential of antiepileptic drug therapy-dosage optimisation. CNS Drugs 2001; 15: 609-621.